Tourmaline Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRML research report →
Range $47.5 – $50
Price Chart
About the company
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED).
- CEO
- Sandeep C. Kulkarni
- IPO
- 2021
- Employees
- 74
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on TRML
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.23B
- P/E
- -26.80
- PEG
- 0.78
- P/S
- 0.00
- P/B
- 4.77
- EV/EBITDA
- -24.55
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17.09%
- ROIC
- -20.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-39,000-18.2%
- Op Income
- $-89,732,000
- Net Income
- $-73,210,000-73.8%
- EPS
- $-2.89+67.4%
- OCF Growth
- -175.1%
- FCF Growth
- -174.6%
- 52W High
- $48.27
- 52W Low
- $11.56
- 50D MA
- $40.68
- 200D MA
- $22.74
- Beta
- 1.58
- RSI (14)
- 89
- Avg Volume
- 925.78K
No earnings-call transcripts are available for TRML yet.
- Free Float
- 65.4%
- Shares Outstanding
- 25.69M
- Float Shares
- 16.80M
of shares held by institutions
107 13F filers
Buy/sell ratio 0.04. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Qiming U.S. Ventures Management, LLC | 741.69K | 0 |
| Nuveen Asset Management, LLC | 76.25K | ▲ 13.50K |
| Allostery Investments LP | 9.36K | ▲ 9.36K |
| Point72 Asia (Singapore) Pte. Ltd. | 4.64K | ▲ 4.64K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 25 | SIEGALL CLAY B | sell | 16,800 |
| Oct 28, 25 | SIEGALL CLAY B | sell | 15,000 |
| Oct 28, 25 | SIEGALL CLAY B | sell | 20,000 |
| Oct 28, 25 | Thiara Parvinder | sell | 16,800 |
| Oct 28, 25 | Thiara Parvinder | other | 83,782 |
| Oct 28, 25 | Thiara Parvinder | sell | 10,000 |
| Oct 28, 25 | Thiara Parvinder | sell | 10,000 |
| Oct 28, 25 | Srivastava Sapna | sell | 20,000 |
| Oct 28, 25 | Srivastava Sapna | sell | 16,800 |
| Oct 28, 25 | Srivastava Sapna | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRML coverage
Recent articles, reports, and earnings notes.
No research on TRML yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRML report →Novartis completes acquisition of Tourmaline Bio
globenewswire.com · Oct 28
Novartis announces expiration of Tourmaline Bio tender offer
globenewswire.com · Oct 28
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
globenewswire.com · Oct 22
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
businesswire.com · Oct 6
Novartis announces commencement of tender offer to acquire Tourmaline Bio
globenewswire.com · Sep 29
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)
prnewswire.com · Sep 15
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
businesswire.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.